Mangalam Drugs And Organics Limited — Updates, 19-09-2025: General Updates

Mangalam Drugs' FY25 revenue fell to ₹318.73 Cr, yet PAT improved to ₹6.72 Cr from a loss. The company expanded its anti-malaria API portfolio with Pyronaridine and initiated in-house critical API manufacturing. A merger scheme was approved by the Board, and subsidiary property revaluation added ₹7.08 Cr surplus. No dividend proposed.